Reata Pharmaceuticals (RETA) Reports Q2 Loss of $0.05/Share

Reata Pharmaceuticals (NASDAQ: RETA) reported Q2 EPS of ($0.05), versus ($0.11) reported last year. Revenue for the quarter came in at $12.4 million, versus $12.4 million reported last year.

For earnings history and earnings-related data on Reata Pharmaceuticals (RETA) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• S&P 500 may pull back before midterms, but Citi says buy the dip
• ZKH Group Limited (ZKH) Reports Q2 EPS of $0.04